United Nations Scientific Committee on the Effects of Atomic Radiation

Totus Medicines Expands its Scientific Advisory Board with the Addition of Dr. Lewis Cantley, Dr. Hope Rugo, and Dr. Josep Tabernero

Retrieved on: 
Wednesday, April 12, 2023
SAB, San Francisco Bay Area, Special Program of Assisted Reproduction, AACR, SPORE, Science and technology in Asia, Vall, ESMO, American Society of Clinical Oncology, Cancer, American Association for Cancer Research, United States Air Force Scientific Advisory Board, Research, Oncology, Signal transduction, European Society for Medical Oncology, Cantley, Ioan Totu, AGIO, Harvard Medical School, ASCO, PI3K, United Nations Scientific Committee on the Effects of Atomic Radiation, Cell biology, Patient, UCSF, Drug discovery, Society, Agios Pharmaceuticals, IDeA Networks of Biomedical Research Excellence, Breast cancer, Disease, Pharmaceutical industry, Antibiotics, Medical device

To start, Totus has focused on oncology with an early breakthrough for the most mutated oncogene in cancer, PI3Kα, using the Totus Accel™ Platform.

Key Points: 
  • To start, Totus has focused on oncology with an early breakthrough for the most mutated oncogene in cancer, PI3Kα, using the Totus Accel™ Platform.
  • They include:
    Dr. Lewis Cantley : Dr. Cantley's work has helped define the field of signal transduction, and he notably discovered the PI3K pathway and its role in cancer.
  • "I am excited to join the Scientific Advisory Board of Totus Medicines.
  • The SAB advances Totus' efforts to continue to deliver unparalleled efficiency and accuracy with its groundbreaking drug discovery platform.

Global Radiation Dose Management Market to Reach $586.7 Million by 2032 - Exclusive DeepTech M-A-P™ Analysis by BIS Research

Retrieved on: 
Friday, December 16, 2022
Fujifilm, United Nations Scientific Committee on the Effects of Atomic Radiation, Degenerative disease, Benchmarking, Sectra AB, Canon Inc., UNSCEAR, Name, Software, Angiography, Center for Urban and Regional Analysis, Bayer, Research, Prevalence, Medtech, Patient safety, RDM, Radiation, Agfa-Gevaert, Radiation exposure, DMS, COVID-19, Annual report, General Electric Company, Radiology, Intermountain Healthcare, Risk, Medical imaging, Vaccine, Pharmaceutical industry, Guerbet

FREMONT, Calif., Dec. 16, 2022 /PRNewswire/ -- BIS Research, the global leader in providing market intelligence on deep technologies, has released its latest study titled Radiation Dose Management Market - A Global and Regional Analysis.

Key Points: 
  • FREMONT, Calif., Dec. 16, 2022 /PRNewswire/ -- BIS Research, the global leader in providing market intelligence on deep technologies, has released its latest study titled Radiation Dose Management Market -A Global and Regional Analysis.
  • According to this study, the global radiation dose management market was valued at $212.8 million in 2021 and is projected to reach $586.7 million by 2032.
  • Growing awareness and initiatives for radiation dose management are expected to push the adoption of dose management software.
  • Our strategic market analysis emphasizes on market estimations, technology analysis, emerging high-growth applications, deeply segmented granular country-level market data, and other important market parameters useful in the strategic decision-making for senior management.

Global Radiation Dose Management Market to Reach $586.7 Million by 2032 - Exclusive DeepTech M-A-P™ Analysis by BIS Research

Retrieved on: 
Friday, December 16, 2022
Fujifilm, United Nations Scientific Committee on the Effects of Atomic Radiation, Degenerative disease, Benchmarking, Sectra AB, Canon Inc., UNSCEAR, Name, Software, Angiography, Center for Urban and Regional Analysis, Bayer, Research, Prevalence, Medtech, Patient safety, RDM, Radiation, Agfa-Gevaert, Radiation exposure, DMS, COVID-19, Annual report, General Electric Company, Radiology, Intermountain Healthcare, Risk, Medical imaging, Vaccine, Pharmaceutical industry, Guerbet

FREMONT, Calif., Dec. 16, 2022 /PRNewswire/ -- BIS Research, the global leader in providing market intelligence on deep technologies, has released its latest study titled Radiation Dose Management Market - A Global and Regional Analysis.

Key Points: 
  • FREMONT, Calif., Dec. 16, 2022 /PRNewswire/ -- BIS Research, the global leader in providing market intelligence on deep technologies, has released its latest study titled Radiation Dose Management Market -A Global and Regional Analysis.
  • According to this study, the global radiation dose management market was valued at $212.8 million in 2021 and is projected to reach $586.7 million by 2032.
  • Growing awareness and initiatives for radiation dose management are expected to push the adoption of dose management software.
  • Our strategic market analysis emphasizes on market estimations, technology analysis, emerging high-growth applications, deeply segmented granular country-level market data, and other important market parameters useful in the strategic decision-making for senior management.

A2 Bio Identifying Solid Tumor Patients for Possible Inclusion in Phase 1 Studies Targeting CEA and Mesothelin Expected to Begin in 2023: Update at SITC 2022

Retrieved on: 
Monday, November 7, 2022
Research, Venture Capital, Clinical Trials, Professional Services, Biotechnology, Health, Pharmaceutical, Science, Oncology, Molecule, Doctor of Philosophy, NYU, Patient, United Nations Scientific Committee on the Effects of Atomic Radiation, Tempus, Society for Immunotherapy of Cancer, Therapy, Neoplasm, NGS, CGMP, CEA, Section 32, Cell, Department, Consultant, HLA, Division, Immunotherapy, Annual general meeting, David Geffen School of Medicine at UCLA, Lung, Pancreatic cancer, UCLA, StepStone Group, MD Anderson Cancer Center, Oncology, Pancreatic Cancer Action, Medicine, Regent, Lung cancer, MSLN, Principal investigator, Cancer immunotherapy, Society, SITC, Poster, Mayo Clinic, Pharmaceutical industry, Medical imaging, Merck, MD, Schroders

Patients who may benefit from this therapy can be identified by using the Tempus diagnostic to pre-screen patients whose tumors have lost HLA-A*02.

Key Points: 
  • Patients who may benefit from this therapy can be identified by using the Tempus diagnostic to pre-screen patients whose tumors have lost HLA-A*02.
  • Once patients are identified, their T cells may be banked early in their disease course for potential utilization in a Phase 1 study in the event of relapse.
  • We are thrilled to enroll patients at BASECAMP-1 and get them prepped for potential inclusion in Phase 1 studies in 2023.
  • The Tmod mechanism utilizes two receptors to exploit common, specific gene losses in tumors that distinguish tumor from normal cells.

Sines geographic importance within the scope of the EU and Global Digital Transition boosted with EllaLink

Retrieved on: 
Friday, January 14, 2022
City, British Oceanographic Data Centre, Electricity, START, ANACOM, Conference, Safety, National, APAC, Union, Innovation, Science, CEO, GLOBE, Foundation, Renewable energy in the European Union, BAE Systems Maritime – Maritime Services, CAP, Ecosystem, Water, United Nations Scientific Committee on the Effects of Atomic Radiation, Natural Resources, Communications satellite, Renewable energy, Atlantic Ocean, Investment, EllaLink, Technology, Data

The creation of an EU-Atlantic Data Gateway Platform in Sines was seen as a way to ensure the Portuguese city's strategic importance to the European Union's digital policy.

Key Points: 
  • The creation of an EU-Atlantic Data Gateway Platform in Sines was seen as a way to ensure the Portuguese city's strategic importance to the European Union's digital policy.
  • "For these countries, the EllaLink cable is of paramount importance to connect them to the rest of the world," he added.
  • "Sines should attract other investments in fiber optic cables and datacenters aimed at the European market," he said.
  • This Conference was organised under the Invest in Alentejo programme, led by ADRAL Alentejo Regional Development Agency , and co-funded by Alentejo 2020.

Poxel Reports Financial Results for First Half 2021 and Provides a Corporate Update

Retrieved on: 
Thursday, September 23, 2021
Research, Diabetes, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, EUR, Goal, Type 2 diabetes, Trial, Senior, Program, POC, ILC, Scientific communication, Chronic kidney disease, Director, ALD, TIMES, Inflammation, Investor relations, JPY, Lists of diseases, Association, Public relations, Adult, NASH, CEO, European Association for the Study of the Liver, Disease, Drug development, Male, AMN, VLCFA, Conditional sentence, Fatty liver disease, United Nations Scientific Committee on the Effects of Atomic Radiation, Pharmacology, Plasma, Tablet, EASL, Exocrine gland, Corporate communication, USD, Achievement, FXR, Therapy, Degenerative disease, Adrenoleukodystrophy, R, Pharmacokinetics, Nervous system, Sumitomo Dainippon Pharma, Euronext, Annual, Patient, Metaves, Imeglimin, Biomarker, Board, AMPK, IPF, Efficacy, CKD, Pharmaceutical industry, Medical device, Management

This achievement has strengthened our near-term financial position and will continue to enhance our financial foundation with associated future royalties and sales-based payments, said Thomas Kuhn, CEO of Poxel.

Key Points: 
  • This achievement has strengthened our near-term financial position and will continue to enhance our financial foundation with associated future royalties and sales-based payments, said Thomas Kuhn, CEO of Poxel.
  • Poxel is well-positioned to leverage its existing platforms to develop therapeutics in rare metabolic diseases, Mr. Kuhn concluded.
  • In July 2021, Poxel received a milestone payment of JPY 1.75 billion (approximately EUR 13.2 million, USD 15.8 million)1 from Sumitomo Dainippon Pharma.
  • Revenue for the first half of 2021 mostly reflects the JPY 1.75 billion (EUR 13.2 million) milestone payment from Sumitomo Dainippon Pharma which Poxel received in July 2021.